LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
18 hedge funds and large institutions have $95.5M invested in LAVA Therapeutics in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 10 closing their positions.
1.77% less ownership
Funds ownership: 36.38% → 34.61% (-1.8%)
25% less funds holding
Funds holding: 24 → 18 (-6)
31% less capital invested
Capital invested by funds: $139M → $95.5M (-$43.6M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.68M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$724K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$161K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$18.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.02M |
| 2 |
Millennium Management
New York
|
-$1.08M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
-$851K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$820K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$456K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PHK
26
Point72 Hong Kong
Hong Kong
| – | -$142K | -9,355 | Closed |
|
27
Point72 Asset Management
Stamford,
Connecticut
| – | -$84K | -5,561 | Closed |
|
|
DKCM
28
Davidson Kempner Capital Management
New York
| – | -$30K | -2,000 | Closed |
|
LVTX Hedge Fund Activity: Q2 2021 in Review
18 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q2 2021, worth a combined $95.5M — down 31% from $139M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LVTX and 4 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $1.68M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $3.02M sold.
- 18 institutional investors held LAVA Therapeutics (LVTX) as of Q2 2021, down from 24 in Q1 2021.
- Funds reported $95.5M of LAVA Therapeutics stock for Q2 2021, down 31% quarter-over-quarter.
- 4 funds opened new LAVA Therapeutics positions in Q2 2021 and 10 closed out, a net change of -6 holders.
- The largest LAVA Therapeutics buyer in Q2 2021 was DAFNA Capital Management, an estimated $1.68M added.
- The largest LAVA Therapeutics seller in Q2 2021 was Monashee Investment Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q2 2021.